ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,262,606 | -37.1% | 237,779 | +12.9% | 0.00% | – |
| Q2 2023 | $2,007,104 | +34.0% | 210,609 | +54.7% | 0.00% | – |
| Q1 2023 | $1,497,705 | -23.0% | 136,155 | +3.6% | 0.00% | – |
| Q4 2022 | $1,944,320 | -18.4% | 131,373 | +5.4% | 0.00% | -100.0% |
| Q3 2022 | $2,382,000 | +17.1% | 124,609 | +30.6% | 0.00% | – |
| Q2 2022 | $2,034,000 | +9.6% | 95,427 | -1.0% | 0.00% | – |
| Q1 2022 | $1,856,000 | -8.3% | 96,346 | -1.2% | 0.00% | – |
| Q4 2021 | $2,023,000 | -10.9% | 97,523 | +2.6% | 0.00% | – |
| Q3 2021 | $2,271,000 | -4.4% | 95,064 | +9.2% | 0.00% | – |
| Q2 2021 | $2,376,000 | -5.5% | 87,079 | +0.2% | 0.00% | -100.0% |
| Q1 2021 | $2,514,000 | +34.4% | 86,901 | +30.6% | 0.00% | – |
| Q4 2020 | $1,871,000 | +12.8% | 66,527 | +17.5% | 0.00% | – |
| Q3 2020 | $1,659,000 | +55.6% | 56,611 | +60.6% | 0.00% | – |
| Q2 2020 | $1,066,000 | +48.5% | 35,255 | +46.4% | 0.00% | – |
| Q1 2020 | $718,000 | – | 24,084 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |